• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MERAIODE: A Phase II Redifferentiation Trial with Trametinib and I in Metastatic Radioactive Iodine Refractory Mutated Differentiated Thyroid Cancer.

作者信息

Leboulleux Sophie, Benisvy Daniele, Taieb David, Attard Marie, Bournaud Claire, Terroir-Cassou-Mounat Marie, Lacroix Ludovic, Anizan Nadege, Schiazza Aurelie, Garcia Marie Eve, Ghuzlan Abir Al, Lamartina Livia, Schlumberger Martin, Godbert Yann, Borget Isabelle

机构信息

Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and University Paris Saclay, Villejuif, France.

Department of Endocrinology, Diabetology, Nutrition and Therapeutic Education, Hôpitaux Universitaires de Genève, Geneve, Switzerland.

出版信息

Thyroid. 2023 Sep;33(9):1124-1129. doi: 10.1089/thy.2023.0240. Epub 2023 Jul 26.

DOI:10.1089/thy.2023.0240
PMID:37350119
Abstract
摘要

相似文献

1
MERAIODE: A Phase II Redifferentiation Trial with Trametinib and I in Metastatic Radioactive Iodine Refractory Mutated Differentiated Thyroid Cancer.MERAIODE：一项曲美替尼与I联合用于转移性放射性碘难治性突变分化型甲状腺癌的II期再分化试验。
Thyroid. 2023 Sep;33(9):1124-1129. doi: 10.1089/thy.2023.0240. Epub 2023 Jul 26.
2
Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer.达拉非尼和曲美替尼用于放射性碘难治性突变型晚期分化型甲状腺癌再分化和治疗的药代动力学/药效学
Thyroid. 2023 Nov;33(11):1327-1338. doi: 10.1089/thy.2023.0228. Epub 2023 Oct 12.
3
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.一项评估达拉非尼联合曲美替尼和放射性碘 131 治疗转移性放射性碘难治性 BRAF p.V600E 突变型分化型甲状腺癌的 II 期再分化试验。
Clin Cancer Res. 2023 Jul 5;29(13):2401-2409. doi: 10.1158/1078-0432.CCR-23-0046.
4
Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.丝裂原活化蛋白激酶通路抑制在放射性碘难治性分化型甲状腺癌再分化中的应用：一项不断发展的方案。
Thyroid. 2019 Nov;29(11):1634-1645. doi: 10.1089/thy.2019.0143.
5
Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions.放射性碘难治性分化型甲状腺癌的治疗优化：现状与未来方向
Minerva Endocrinol. 2012 Dec;37(4):335-56.
6
A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer.一项使用维甲酸作为再分化剂以增加转移性甲状腺癌碘摄取的II期研究。
Clin Oncol (R Coll Radiol). 2004 Dec;16(8):569-74. doi: 10.1016/j.clon.2004.06.018.
7
Novel Therapeutics for Advanced Differentiated Thyroid Cancer.新型治疗分化型甲状腺癌的药物。
Endocrinol Metab Clin North Am. 2022 Jun;51(2):367-378. doi: 10.1016/j.ecl.2021.11.019. Epub 2022 May 4.
8
Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study.MAPK 抑制增强放射性碘难治性甲状腺癌摄取放射性碘（ERRITI）：一项单中心前瞻性双臂研究。
Clin Cancer Res. 2022 Oct 3;28(19):4194-4202. doi: 10.1158/1078-0432.CCR-22-0437.
9
Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer.放射性碘难治性分化型甲状腺癌的分子机制与靶向治疗进展。
Med Oncol. 2023 Jul 31;40(9):258. doi: 10.1007/s12032-023-02098-3.
10
Perspective: The Molecular Landscape of Radioactive Iodine Refractory Differentiated Thyroid Cancer and Poorly Differentiated Thyroid Cancer.视角：放射性碘难治性分化型甲状腺癌和低分化甲状腺癌的分子图谱
Thyroid. 2023 Feb;33(2):138-142. doi: 10.1089/thy.2022.0428. Epub 2022 Nov 30.

引用本文的文献

1
BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications.实体瘤中的BRAF靶向治疗：分子层面与临床应用
Int J Mol Sci. 2025 Apr 16;26(8):3757. doi: 10.3390/ijms26083757.
2
Durable Response to Redifferentiation in a Patient With Metastatic Fusion-driven Papillary Thyroid Cancer.转移性融合驱动型甲状腺乳头状癌患者对再分化的持久反应
JCEM Case Rep. 2025 May 5;3(6):luaf054. doi: 10.1210/jcemcr/luaf054. eCollection 2025 Jun.
3
Genetic mutations and prognostic indicators in differentiated thyroid cancer: a molecular perspective.
分化型甲状腺癌中的基因突变与预后指标：分子视角
Turk J Med Sci. 2024 Dec 25;55(1):72-81. doi: 10.55730/1300-0144.5944. eCollection 2025.
4
Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?选择性激酶抑制剂是否改变了放射性碘难治性甲状腺癌患者的治疗方式？
Eur Thyroid J. 2025 Feb 7;14(1). doi: 10.1530/ETJ-24-0332. Print 2025 Feb 1.
5
Redifferentiation Therapies in Thyroid Oncology: Molecular and Clinical Aspects.甲状腺肿瘤学中的再分化疗法：分子与临床方面
J Clin Med. 2024 Nov 21;13(23):7021. doi: 10.3390/jcm13237021.
6
Systemic treatments for radioiodine-refractory thyroid cancers.放射性碘难治性甲状腺癌的系统治疗。
Front Endocrinol (Lausanne). 2024 Oct 15;15:1346476. doi: 10.3389/fendo.2024.1346476. eCollection 2024.
7
An update on redifferentiation strategies for radioactive iodine-refractory differentiated thyroid carcinoma.放射性碘难治性分化型甲状腺癌再分化策略的最新进展
Endocrine. 2025 Jan;87(1):1-10. doi: 10.1007/s12020-024-04018-5. Epub 2024 Sep 4.
8
Molecular Perspectives in Radioactive Iodine Theranostics: Current Redifferentiation Protocols for Mis-Differentiated Thyroid Cancer.放射性碘诊疗学的分子视角：分化型甲状腺癌的当前再分化方案
J Clin Med. 2024 Jun 21;13(13):3645. doi: 10.3390/jcm13133645.
9
[Thyroid carcinomas: the role of systemic therapies in internal medicine].[甲状腺癌：全身治疗在内科中的作用]
Inn Med (Heidelb). 2024 Jul;65(7):642-655. doi: 10.1007/s00108-024-01728-w. Epub 2024 Jun 20.
10
Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy.免疫治疗时代滤泡源性甲状腺癌的新兴治疗选择。
Front Immunol. 2024 May 29;15:1369780. doi: 10.3389/fimmu.2024.1369780. eCollection 2024.